PPARA and atherosclerosis: Furthermore, the effect of PPAR agonist on CD4+ T cells impaired theiraction on monocytes and EC, suggesting that PPAR modulation of inflammatorypathways in T cells may offer clinical benefits in atherosclerosis [43].